prikaz prve stranice dokumenta Angiotensin-converting enzyme insertion/deletion gene polymorphism and interferon-β treatment response in multiple sclerosis patients: a preliminary report.
  Download
PDF 121.15 KB
Scientific paper - Preliminary note / Short communication
Angiotensin-converting enzyme insertion/deletion gene polymorphism and interferon-β treatment response in multiple sclerosis patients: a preliminary report.
Pharmacogenetics and Genomics, 27 (2017), 6; 232-235. urn:nbn:hr:184:925452
Ristić, Smiljana; Starčević Čizmarević, Nada; Lavtar, Polona; Lovrečić, Luca; Perković, Olivio; Sepčić, Juraj; Šega Jazbec, Saša; Kapović, Miljenko; Peterlin, Borut.

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Ristić, S., Starčević Čizmarević, N., Lavtar, P., Lovrečić, L., Perković, O., Sepčić, J. ... Peterlin, B. (2017). Angiotensin-converting enzyme insertion/deletion gene polymorphism and interferon-β treatment response in multiple sclerosis patients: a preliminary report.. Pharmacogenetics and Genomics, 27. (6), 232-235. Retrieved from https://urn.nsk.hr/urn:nbn:hr:184:925452

Ristić, Smiljana, et al. "Angiotensin-converting enzyme insertion/deletion gene polymorphism and interferon-β treatment response in multiple sclerosis patients: a preliminary report.." Pharmacogenetics and Genomics, vol. 27, no. 6, 2017, pp. 232-235. https://urn.nsk.hr/urn:nbn:hr:184:925452

Ristić, Smiljana, Nada Starčević Čizmarević, Polona Lavtar, Luca Lovrečić, Olivio Perković, Juraj Sepčić, Saša Šega Jazbec, Miljenko Kapović and Borut. Peterlin. "Angiotensin-converting enzyme insertion/deletion gene polymorphism and interferon-β treatment response in multiple sclerosis patients: a preliminary report.." Pharmacogenetics and Genomics 27, no. 6 (2017): 232-235. https://urn.nsk.hr/urn:nbn:hr:184:925452

Ristić, S., et al. (2017) 'Angiotensin-converting enzyme insertion/deletion gene polymorphism and interferon-β treatment response in multiple sclerosis patients: a preliminary report.', Pharmacogenetics and Genomics, 27(6), pp. 232-235. Available at: https://urn.nsk.hr/urn:nbn:hr:184:925452 (Accessed 26 November 2024)

Ristić S, Starčević Čizmarević N, Lavtar P, Lovrečić L, Perković O, Sepčić J, and sur.. Angiotensin-converting enzyme insertion/deletion gene polymorphism and interferon-β treatment response in multiple sclerosis patients: a preliminary report.. Pharmacogenetics and Genomics [Internet]. 2017 [cited 2024 November 26];27(6):232-235. Available at: https://urn.nsk.hr/urn:nbn:hr:184:925452

S. Ristić, et al., "Angiotensin-converting enzyme insertion/deletion gene polymorphism and interferon-β treatment response in multiple sclerosis patients: a preliminary report.", Pharmacogenetics and Genomics, vol. 27, no. 6, pp. 232-235, 2017. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:925452. [Accessed: 26 November 2024]

Metadata
Title (english)Angiotensin-converting enzyme insertion/deletion gene polymorphism and interferon-β treatment response in multiple sclerosis patients: a preliminary report.
AuthorSmiljana Ristić
AuthorNada Starčević Čizmarević
AuthorPolona Lavtar
AuthorLuca Lovrečić
AuthorOlivio Perković
AuthorJuraj Sepčić
MBZ: 64815
AuthorSaša Šega Jazbec
AuthorMiljenko Kapović
AuthorBorut. Peterlin
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Biology and Medical Genetics)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Human Genetics, Genomics and Proteomics
Abstract (english)
We investigated the effect of the functional insertion/ deletion (I/D) polymorphism in the angiotensin- converting enzyme (ACE) gene on the response to interferon-β (IFN-β) therapy in Croatian and Slovenian patients with multiple sclerosis (MS). A total of 275 IFN-β treated MS patients [162 responders (Rs) and 113 nonresponders (NRs)] were genotyped by PCR. The ACE I/D genotype distribution and allele frequencies did not differ between female Rs and NRs. However, male NRs tended to have a greater prevalence of the DD genotype (P=0.073 ; odds ratio: 2.64 ; 95% confidence interval: 0.91–7.60) and a significantly higher frequency of the D allele (P=0.022 ; odds ratio: 2.43 ; 95% confidence interval: 1.13–5.20) than male Rs. Multiple forward stepwise regression analysis indicated that the negative response to IFN-β therapy was associated with the ACE-DD genotype in men ( β=0.371 ; multiple R2 change: 0.132 ; P=0.009) and a higher pretreatment relapse rate in both men ( β=−0.438 ; multiple R2 change: 0.135 ; P=0.015) and women ( β=−0.208 ; multiple R2 change: 0.042 ; P=0.034). The ACE I/D polymorphism and pretreatment relapse rate accounted for ∼26.7% of the IFN-β response variability among the men in the sample. Further studies of a larger number of MS patients from different populations are necessary to evaluate these preliminary findings.
Keywords (english)
Languageenglish
Publication typeScientific paper - Preliminary note / Short communication
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titlePharmacogenetics and Genomics
Numberingvol. 27, no. 6, pp. 232-235
p-ISSN1744-6872
URN:NBNurn:nbn:hr:184:925452
Publication2017
Document URLhttp://bib.irb.hr/873428
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2017-09-26 19:54:01